Low incidence of transplantation-related acute complications in patients with chronic myeloid leukemia undergoing allogeneic stem cell transplantation with a low-dose (550 cGy) total body irradiation conditioning regimen

Biology of Blood and Marrow Transplantation

Volumn 7, Issue 6, 2001, Pages 352-358

  Khoury, H ^a   Adkins, D ^a   Brown, R ^a   Pence, H ^a   Vij, R ^a   Goodnough, L T ^a   Westervelt, P ^a   Trinkaus, K ^a   Lin, H S ^a   DiPersio, J ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Chronic myeloid leukemia; Single dose total body irradiation; Transplant related toxicity

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; CYTOKINE; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HLA A ANTIGEN; HLA ANTIGEN CLASS 2; HLA B ANTIGEN; HLA DR ANTIGEN; IMMUNOSUPPRESSIVE AGENT; METHYLPREDNISOLONE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ADULT; ALLOGRAFT; ARTICLE; CANCER MORTALITY; CANCER RECURRENCE; CANCER SURVIVAL; CHEMOPROPHYLAXIS; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; FEMALE; FOLLOW UP; GRAFT FAILURE; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HLA MATCHING; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; LEUKEMIA REMISSION; MALE; PERIPHERAL BLOOD STEM CELL; PHASE 2 CLINICAL TRIAL; RADIATION DOSE; SIBLING; SIDE EFFECT; WHOLE BODY RADIATION;

EID: 0034923686     PISSN: 10838791     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1083-8791(01)80006-9     Document Type: Article

References (36)

1. Population-based age and sex-specific incidence rates in the 4 main types of leukemia
2. Cancer incidence and survival in patients 65 years of age and older
3. Graft-versus-leukemia reactions after bone marrow transplantation
4. Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation
5. Long-term follow-up of patients who achieved complete remission after donor leukocyte infusions
6. Treatment of chronic granulocytic leukemia with chemoradiotherapy and transplantation of marrow from identical twins
7. Allogeneic marrow transplantation in patients with chronic myeloid leukemia in the chronic phase: A randomized trial of two irradiation regimens
8. Long-term results of bone marrow transplantation for patients with AML, ALL, and CML prepared with single dose total body irradiation of 500 cGy delivered with a high dose rate
9. Marrow toxicity of fractionated vs single dose total body irradiation is identical in a canine model
10. Comparison of fractionated to single-dose total body irradiation in conditioning canine littermates for DLA-identical marrow grafts
11. Fractionated versus single-dose total body irradiation at low and high dose rates to condition canine littermates for DLA-identical marrow grafts
12. Factors that influence the collection and engraftment of allogeneic peripheral-blood stem cells in patients with hematologic malignancies
13. Side effects associated with post-transplant G-CSF in patients with chronic myeloid leukemia undergoing allogeneic peripheral blood stem cell transplantation
14. Effect of leukocyte compatibility on neutrophil increment after transfusion of granulocyte colony-stimulating factor-mobilized prophylactic granulocyte transfusions and on clinical outcomes after stem cell transplantation
15. Rapid transfer of DNA from agarose gels to nylon membranes
16. Characterization of a panel of highly variable minisatellites cloned from human DNA
17. Polymerase chain reaction detection of the BCR-ABL fusion transcript after allogeneic marrow transplantation for CML: Results and implications in 346 patients
18. Should PCR analysis to detect minimal residual disease in patients with CML be used in clinical decision making?
19. Nonparametric estimation from incomplete information
20. Does early treatment with high-dose methylprednisolone alter the course of hepatic regimen-related toxicity?
21. IBMTR Severity Index for grading acute graft-versus-host disease: Retrospective comparison with Glucksberg grade
22. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HLA-matched sibling donors
23. Risk assessment for patients with chronic myeloid leukemia before allogeneic blood or marrow transplantation
24. An evidence-based analysis of the effect of busulfan, hydroxyurea, interferon, and allogeneic bone marrow transplantation in treating the chronic phase of chronic myeloid leukemia: Developed for the American Society of Hematology
25. Survival with bone marrow transplantation versus hydroxyurea or interferon for chronic myeloid leukemia
26. Total body irradiation and acute graft versus host disease: The role of gastrointestinal damage and inflammatory cytokines
27. The primacy of the gastrointestinal tract as a target organ of acute graft versus host disease: Rationale for the use of cytokine shields in allogeneic bone marrow transplantation
28. Acute graft-versus-host disease: Analysis of risk factors after allogeneic marrow transplantation and prophylaxis with cyclosporine and methotrexate
29. Cyclosporine or cyclosporine plus methylprednisolone for prophylaxis of graft-versus-host disease: A prospective, randomized trial
30. Methotrexate and cyclosporine versus cyclosporine alone for prophylaxis of graft-versus-host disease in patients given HLA-identical marrow grafts for leukemia: Long-term follow-up of a controlled trial
31. Long-term follow-up of high-risk allogeneic peripheral blood stem-cell transplant recipients: Graft-versus-host disease and transplant-related mortality
32. Allogeneic peripheral blood stem cell transplantation may be associated with a high risk of chronic graft-versus-host disease
33. The risk of residual molecular and cytogenetic disease in patients with Philadelphia-chromosome positive first chronic phase chronic myelogenous leukemia is reduced after transplantation of allogeneic peripheral blood compared with bone marrow
34. Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: Harnessing graft-versus-leukemia without myeloablative therapy
35. Outpatient allografting with minimally myelosuppressive, immunosuppressive conditioning of low-dose TBI and postgrafting cyclosporine (CSP) and mycophenolate mofetil (MMF)